Analysts Anticipate Endologix, Inc. (ELGX) Will Announce Earnings of -$0.25 Per Share
Equities analysts forecast that Endologix, Inc. (NASDAQ:ELGX) will post earnings per share of ($0.25) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Endologix’s earnings, with the highest EPS estimate coming in at ($0.19) and the lowest estimate coming in at ($0.33). Endologix posted earnings of ($0.11) per share in the same quarter last year, which indicates a negative year over year growth rate of 127.3%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, November 6th.
According to Zacks, analysts expect that Endologix will report full-year earnings of ($0.86) per share for the current fiscal year, with EPS estimates ranging from ($1.06) to ($0.70). For the next year, analysts forecast that the business will report earnings of ($0.69) per share, with EPS estimates ranging from ($0.91) to ($0.52). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Endologix.
Endologix (NASDAQ:ELGX) last announced its quarterly earnings results on Thursday, August 9th. The medical instruments supplier reported ($0.18) EPS for the quarter, meeting the consensus estimate of ($0.18). Endologix had a negative return on equity of 69.06% and a negative net margin of 40.92%. The company had revenue of $44.70 million for the quarter, compared to the consensus estimate of $44.43 million. During the same quarter last year, the company posted ($0.10) earnings per share. The company’s revenue for the quarter was down 8.0% compared to the same quarter last year.
ELGX stock traded down $0.03 during midday trading on Friday, hitting $1.65. 523,600 shares of the company traded hands, compared to its average volume of 664,227. Endologix has a twelve month low of $1.49 and a twelve month high of $6.72. The company has a quick ratio of 1.20, a current ratio of 1.90 and a debt-to-equity ratio of 5.37. The company has a market cap of $161.79 million, a PE ratio of -3.44 and a beta of 0.01.
In related news, CFO Vaseem Mahboob acquired 30,000 shares of the stock in a transaction dated Thursday, August 16th. The shares were acquired at an average price of $2.43 per share, for a total transaction of $72,900.00. Following the completion of the purchase, the chief financial officer now owns 146,812 shares in the company, valued at approximately $356,753.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.10% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. MetLife Investment Advisors LLC lifted its position in Endologix by 128.2% in the second quarter. MetLife Investment Advisors LLC now owns 41,313 shares of the medical instruments supplier’s stock worth $234,000 after purchasing an additional 23,210 shares during the period. Schwab Charles Investment Management Inc. lifted its position in Endologix by 8.7% in the first quarter. Schwab Charles Investment Management Inc. now owns 380,648 shares of the medical instruments supplier’s stock worth $1,611,000 after purchasing an additional 30,585 shares during the period. C WorldWide Group Holding A S lifted its position in Endologix by 22.3% in the second quarter. C WorldWide Group Holding A S now owns 364,464 shares of the medical instruments supplier’s stock worth $2,063,000 after purchasing an additional 66,486 shares during the period. Engineers Gate Manager LP bought a new position in Endologix in the second quarter worth $442,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in Endologix by 14.0% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,431,962 shares of the medical instruments supplier’s stock worth $8,105,000 after purchasing an additional 175,970 shares during the period. Institutional investors and hedge funds own 94.03% of the company’s stock.
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.
See Also: What is the balance sheet?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.